Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features

(2012) Jaime Prat   VIRCHOWS ARCHIV

Transcriptional and post-translational regulation of hyaluronan synthesis

(2011) Raija H. Tammi et al.   FEBS Journal

Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis

(2011) Miranda Ween et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts

(2010) Ilaria De Stefano et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hyaluronan in human malignancies

(2010) R.K. Sironen et al.   EXPERIMENTAL CELL RESEARCH

Expression of Hyaluronan Synthases (HAS1–3) and Hyaluronidases (HYAL1–2) in Serous Ovarian Carcinomas: Inverse Correlation between HYAL1 and Hyaluronan Content

(2009) Timo K Nykopp et al.   BMC CANCER

Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides

(2009) M. G. Slomiany et al.   CLINICAL CANCER RESEARCH

Tumor Necrosis Factor-α Regulates Transforming Growth Factor-β-dependent Epithelial-Mesenchymal Transition by Promoting Hyaluronan-CD44-Moesin Interaction

(2009) Eri Takahashi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ovarian cancer

(2009) Bryan T Hennessy et al.   LANCET

A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity

(2008) A. Banzato et al.   CLINICAL CANCER RESEARCH

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

(2008) Martin Köbel et al.   PLOS MEDICINE